Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Adam E. Welker"'
Autor:
Beatrice Philip, Diana X. Yu, Mark R. Silvis, Clifford H. Shin, James P. Robinson, Gemma L. Robinson, Adam E. Welker, Stephanie N. Angel, Sheryl R. Tripp, Joshua A. Sonnen, Matthew W. VanBrocklin, Richard J. Gibbons, Ryan E. Looper, Howard Colman, Sheri L. Holmen
Publikováno v:
Cell Reports, Vol 23, Iss 5, Pp 1553-1564 (2018)
Summary: Isocitrate dehydrogenase 1 (IDH1) is the most commonly mutated gene in grade II–III glioma and secondary glioblastoma (GBM). A causal role for IDH1R132H in gliomagenesis has been proposed, but functional validation in vivo has not been dem
Externí odkaz:
https://doaj.org/article/2d92767aaa004267a8ec8cf27e3f8ef6
Autor:
Sheri L. Holmen, James P. Robinson, Matthew W. VanBrocklin, Diana X. Yu, Joshua A. Sonnen, Clifford Shin, Adam E. Welker
Publikováno v:
Oncogene
Heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) is a ligand for the epidermal growth factor receptor (EGFR), one of the most commonly amplified receptor tyrosine kinases (RTK) in glioblastoma. While HBEGF has been found to be
Autor:
James P. Robinson, Diana X. Yu, Stephanie N. Angel, Ryan E. Looper, Clifford Shin, Mark R. Silvis, Sheri L. Holmen, Beatrice Philip, Howard Colman, Joshua A. Sonnen, Adam E. Welker, Richard J. Gibbons, Gemma L. Robinson, Sheryl R. Tripp, Matthew W. VanBrocklin
Publikováno v:
Cell reports
Cell Reports, Vol 23, Iss 5, Pp 1553-1564 (2018)
Cell Reports, Vol 23, Iss 5, Pp 1553-1564 (2018)
SUMMARY Isocitrate dehydrogenase 1 (IDH1) is the most commonly mutated gene in grade II–III glioma and secondary glioblastoma (GBM). A causal role for IDH1R132H in gliomagenesis has been proposed, but functional validation in vivo has not been demo
Autor:
Howard Colman, Beatrice Philip, Mark R. Silvis, Adam E. Welker, Sheri L. Holmen, Clifford Shin, James P. Robinson, Joshua A. Sonnen, Matthew W. VanBrocklin, Diana Yu
Publikováno v:
Neuro-Oncology. 19:vi263-vi264
Publikováno v:
Neuro-Oncology. 19:vi261-vi261
Activating mutations in BRAF have been identified in a significant number of human cancers including both pediatric and adult gliomas of varying grades. Specifically, the BRAFV600E mutation, which is the most common mutational variant, has been found